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’ INTRODUCTION
A major component of the adaptive immune response to
infection is the generation of protective and long-lasting humoral
immunity, but factors governing selection of the particular antigens
recognized are unclear.1,2 It is not uncommon for viruses encoding
a small number of proteins to generate antibodies against each
encoded protein. But for infectious agents containing hundreds
or thousands of proteins only a subset of the proteome is
recognized and little is known about the extent or the
characterisitics of this subset of antigens. Methods for making a
complete empirical accounting of the immunoproteome have
limitations, particularly when the genome of the organism is
large. Here we describe a B. melitensis proteome microarray that
enables this problem to be directly addressed by applying an
unbiased systems biology approach to identify immunodominant
Received: June 30, 2011
ABSTRACT: A complete understanding of the factors that determine
selection of antigens recognized by the humoral immune response following
infectious agent challenge is lacking. Here we illustrate a systems biology
approach to identify the antibody signature associated with Brucella melitensis
(Bm) infection in humans and predict proteomic features of serodiagnostic
antigens. By taking advantage of a full proteome microarray expressing
previously cloned 1406 and newly cloned 1640 Bm genes, we were able to
identify 122 immunodominant antigens and 33 serodiagnostic antigens. The
reactive antigens were then classified according to annotated functional
features (COGs), computationally predicted features (e.g., subcellular
localization, physical properties), and protein expression estimated by mass
spectrometry (MS). Enrichment analyses indicated that membrane associa-
tion and secretion were significant enriching features of the reactive antigens,
as were proteins predicted to have a signal peptide, a single transmembrane domain, and outermembrane or periplasmic location. These
features accounted for 67% of the serodiagnostic antigens. An overlay of the seroreactive antigen set with proteomic data sets generated
by MS identified an additional 24%, suggesting that protein expression in bacteria is an additional determinant in the induction of
Brucella-specific antibodies. This analysis indicates that one-third of the proteome contains enriching features that account for 91%of the
antigens recognized, and after B. melitensis infection the immune system develops significant antibody titers against 10% of the proteins
with these enriching features. This systems biology approach provides an empirical basis for understanding the breadth and specificity of
the immune response to B. melitensis and a new framework for comparing the humoral responses against other microorganisms.
KEYWORDS: Brucella melitensis, enriching features, immune response, protein microarray
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and serodiagnostic antigens and to classify the reactive antigens
based on functional and physical properties.
Protein microarrays can be used with relative ease to probe the
entire proteome of different infectious microorganisms including
bacteria, viruses and parasites.313 This approach permits assessing
the repertoire of antibodies produced in response to infections or
vaccinations from large collections of individual patient sera, and
can be used to perform large-scale sero-epidemiological and sero-
surveillance analyses not possible with other technologies, while
consuming small quantities (<2 μL) of each serum sample.
Probing large numbers of patient specimens empowers the statistical
tests resulting in more reliable conclusions while correcting for
false discovery required for multiple comparison testing inherent
in microarray analysis.3,5,7,9 Moreover, microarrays can display all
proteins of an infectious agent and may allow for identification of
novel antigens, otherwise undetectable by methods like 2-D gels
that are highly biased by microbial protein expression patterns.
Brucellosis is a worldwide zoonosis caused by bacteria of the
genus Brucella. Brucella melitensis, the most virulent species infecting
humans, also infects goats, sheep and cattle,1416 in Central and
South America, the Middle East, East Asia, and some southern
European countries.17,18 Consumption of animal products, direct
animal contact and inhalation of aerosolized bacteria in the
laboratory setting (indicating the potential for air-borne spread
via a bioterrorism-type attack) are well-recognized routes of
infection. The current knowledge of protein antigens recognized
by humans and reservoir animals is based on limited numbers of
studies on Brucella melitensis and Brucella abortus.1931
We recently constructed a pilot proteome array consisting of
1406 B. melitensis proteins and observed marked differences in
immune responses between humans and goats.5 Here we have
expanded our previous study to the full proteome microarray
consisting of 3046 B. melitensis proteins, by including expression
of newly cloned 1640 Bm genes. In addition to developing a
better classifier capable of predicting disease based on serological
response, more importantly, this study allows an estimate of the
extent of immune reactivity against the whole proteome, and
prediction of proteomic features that may dictate immune recogni-
tion for other yet uncharacterized gram-negative bacteria.
’MATERIALS AND METHODS
Ethics Statement
Human sera were obtained from patients enrolled in a prospec-
tive clinical study of brucellosis in Lima, Peru. The human subjects
part of the studywas approved by theHumansResearch Protections
Committee of theUniversity ofCalifornia SanDiego, theComite de
Etica of Universidad Peruana Cayetano Heredia, Lima, Peru and
the Comite de Etica of Asociacion Benefica PRISMA, Lima, Peru,
all of whom have maintained federal wide assurances with the
United States Department of Health and Human Services. All
patients provided written informed consent prior to enrollment
in the study, and signed consent forms have been stored in locked
files in study offices at UPCH and AB PRISMA, Lima, Peru.
Human Serum Samples
Human sera were obtained from patients in Lima, Peru. All
patients in this studywere infected with B. melitensis biovar 1.
Forty- two patients were confirmed to have acute brucellosis by
positive culture, positive Rose Bengal test and by tube agglutina-
tion tests titers g1/160. Eighteen patients presenting with
brucellosis-compatible syndromes were culture negative and Rose
Bengal positive, and treated according to standard antibiotic
therapy within 2 days of serum sampling. Additional control
patient samples included 13 sera from Rose Bengal-negative
patients, 44 samples from ambulatory healthy controls from
north Lima where brucellosis occasionally affects patients, and
sera from humans in the U.S. where brucellosis is not found.
Brucella melitensis Lipopolysaccharide Purification
Approximately 10 g of autoclaved pellet of B. melitensis 16 M
were used to isolate LPS using the hot phenol-water method.32
The purified LPS was treated with RNase, DNase and Protei-
nase-K, and the hot phenol-water treament was repeated. B.
melitensis LPS obtained from both upper phenol saturated aqu-
eous layer (aqueous phase) and lower water saturated phenol
layer (phenol phase) were pooled. LPS from E. coli 055:B5 was
purchased from Sigma Chemicals (St. Louis, MO). The LPS
from E. coli 055:B5 and B. melitensis 16 M were analyzed on a
gradient 412% Tris-Glycine sodium dodecyl sulfate (SDS)
polyacrylamide gel (Invitrogen Corp., Carlsbad, CA) under redu-
cing conditions. The presence of LPS in the gels was detected
with a periodic acid silver stain33 and protein using Coomassie
blue stain. B. melitensis LPS was quantified using a colorimetric
assay to measure 2-keto-3-deoxyoctonate (KDO) concentration.34
E. coli 055: B5 LPS (Sigma, St. Louis, MO) was used as standard.
Microarray Fabrication, Probing and Immunostrips Probing
All ORFs from Brucella melitensis 16 M genomic DNA were
identified using GenBank NC_003317 and NC_003318, and
1640 ORFs that were absent from pilot chip were amplified and
cloned using a high-throughput PCR and recombination cloning
method described previously.5 Microarrays and immunostrips
were fabricated and probed as described before.5 Plasmids were
expressed at 24 C for 16 h in in vitro transcription/translation
E. coli reactions (Expressway Maxi kits from Invitrogen), accord-
ing to the manufacturer’s instructions. For microarrays, 10 μL of
reaction was mixed with 3.3 μL 0.2% Tween 20 to give a final
concentration of 0.05% Tween 20, and printed onto nitrocellu-
lose coated glass FAST slides (Whatman) using an Omni Grid
100 microarray printer (Genomic Solutions). For immunostrips,
B. melitensis LPS was printed at 0.01 mg/mL. All antigens were
printed on Optitran BA-S 85 0.45 μm Nitrocellulose membrane
(Whatman) using BioJet dispenser (BioDot) at 1μL/cm, and cut
into 3 mm strips. Human sera samples were diluted to 1:200 with
10 mg/mL E. coli lysate (Mclab). Microarray slides were in-
cubated in biotin-conjugated secondary antibody (Jackson Im-
munoResearch) diluted 1/200 in blocking buffer, and detected
by incubation with streptavidin-conjugated SureLight P-3 (Columbia
Biosciences). The slides were washed and air-dried by brief
centrifugation. Microarray slides were scanned and analyzed
using a Perkin-Elmer ScanArray Express HTmicroarray scanner.
Intensities were quantified using QuantArray software. All signal
intensities were corrected for spot-specific background. For
immunostrips probing, human sera were diluted to 1/200 in
5% BSA solution containing 20% E. coli lysate (McLab).
Strips were then incubated in alkaline phosphatase conjugated
donkey antihuman immunoglobulin (anti-IgG, Fcγ fragment-
specific, Jackson ImmunoResearch) secondary antibody, diluted
to 1/2000, and reactive bands were visualized by incubating with
1-step Nitro-Blue Tetrazolium Chloride/5-Bromo-4-Chloro-30-
Indolyphosphate p-Toluidine Salt (NBT/BCIP) developing
buffer (Thermo Fisher Scientific). Immunostrips were scanned
with Hewlett-Packard document scanner, and were quantified
using Image J software.
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Mass Spectrometry Data Set from Pathogen Portal Web Site
The mass spectrometry data set “characterization of host and
pathogen proteins affected by Brucella abortus infection” was
from Caprion Proteomics studies of B abortus, downloadable
from pathogen portal web site hosted by proteomics resource
center at http://www.pathogenportal.org/portal/portal/Path-
Port/Home. Samples were processed for “intact bacteria” or
“cell envelope” preparations from exponentially growing bacteria
according to the Caprion protocol 24401 and 24302, as described
before.23,35 Briefly, to process intact bacteria for MS analysis,
50 μL aliquots of 20 μg protein samples were denatured in
50 mM ammonium bicarbonate (Sigma-Aldrich, St. Louis, MO)
containing 8 M urea. After sonication, samples were centrifuged
at 2000 g for 1 min and a 950 μL cold (20 C) chloroform/
methanol solution (2:1 v/v) were added. Samples were vortex
mixed and incubated at 20 C for 2 h. Subsequently, 100 μL
cold (20 C) methanol was added and samples were clarified
by centrifugation at 21 000 g for 10 min at 4 C. The super-
natants were dried under vacuum, resuspended in 100 mM
ammonium bicarbonate containing 8 M urea and 1% (w/v) of
acid-labile surfactant (ALS; Waters, Milford, MA) and sonicated
for 10 min. After centrifugation for 20 s at 2000 g, samples were
incubated for 1 h at ambient temperature. A volume of 450 μL of
100 mM ammonium bicarbonate containing 5% (v/v) of aceto-
nitrile was added. Lys-C (Wako, Richmond, VA) was added to
yield a 1:50 enzyme to protein ratio. The samples were incubated
for 3 h at 37 C. Trypsin (Promega, Madison, WI) was then
added at a 1:50 enzyme to protein ratio and samples were
incubated for an additional 16 h. Following proteolysis, TCEP
(Pierce, Rockford, IL) was added to a final concentration of
10 mM and samples were incubated for 30 min at ambient
temperature and then lyophilized. To cleave the acid labile surfac-
tant, samples were incubated for 30 min at ambient temperature
in 100 μL of 1 N HCl and 100 μL of water were added into each
sample with subsequent incubation for another half hour at
ambient temperature. To process cell envelope for MS analysis,
supernatants of exponentially growing B. abortus strains were
clarified, centrifuged at 100 000 g for 6 h at 4 C, pellets
resuspended in double distilled water. The sample was sonicated,
and 50 mM ammonium bicarbonate containing 2% acid-labile
surfactant and 8 M urea were added. The sample was vortex
mixed for 1 h. A sample of 50 μL of the OM suspension was added
to a final volume of 1 mL of a chloroform/methanol solution
(2:1 v/v). The sample was vortexmixed and incubated at20 C
for 2 h. Subsequently, 100 μL of cold methanol (20 C) was
added, and the sample was cleared by centrifugation for 10 min at
21 000 g. The supernatant was dried under vacuum and
resuspended in 4 M urea; 50 mM ammonium bicarbonate pH
8.0. Lys-C was added at a 1:50 protein ratio. The samples were
then diluted 4:1 with 50 mM ammonium bicarbonate buffer pH
8.0, and trypsin was added at a 1:25 protein ratio for an additional
16 h. Following proteolysis, the samples were distributed into
96-well plates for mass spectrometry analysis.
Peptide digests were analyzed by liquid chromatography coupled
to mass spectrometry (LC-MS) as described.23,35,36 The LCMS
system consisted of a CapLC (Waters, Milford, MA) with a
cooled autosampler and a QTOF Ultima (Waters, Milford, MA)
controlled by MassLynx version 4.0 software. The peptide con-
centrations were normalized and the samples were injected into a
reversed-phase column (Jupiter C18, Phenomenex, Torrance,
CA) for HPLC separation. Protein identification was done by
submitting LCMS spectra to Mascot software (MatrixScience,
Boston, MA) for searching against the National Center for
Biotechnology Information protein database (NCBI). The para-
meters used for Mascot search and protein homology cluster-
ing were previously detailed.23,35 Numbers of different peptides
for each identified protein were counted and listed in Table S4
(Supporting Information).
Data Analysis
Data analysis was performed using the R (http://www.
r-project.org) and SAS (http://www.sas.com/) statistical software.
It has been noted in literature that data derived from microarray
platforms is heteroskedatic.3739 To stabilize the variance,40,41
the vsn normalization method implemented as part of the Biocon-
ductor suite (www.bioconductor.org) was applied to the quanti-
fied array intensities. In addition to removing heteroskedacity,
this procedure corrects for nonspecific noise effects by finding
maximum likelihood shifting and scaling parameters for each
array such that control probe variance is minimized. This calibration
has been shown to be effective on a number of platforms.42
Differentially reactive proteins between groups were deter-
mined using a Bayes regularized t test adapted from Cyber-T for
protein arrays,37,43 which has been shown to be more effective
than other differential expression techniques.44 To account for
multiple comparison conditions, the Benjamini and Hochberg
(BH)method was used to control the false discovery rate.45 After
Benjamini and Hochberg correction, p-value smaller than 0.05
was considered significant, and the corresponding protein was
considered differentially reactive and serodiagnostic. Multiplex
classifiers were constructed using linear and nonlinear Support
Vector Machines (SVMs) using the “e1071” R package. Plots of
receiver operating characteristic (ROC) curves were made with
the “ROCR” R package. Sensitivity specificity and Area Under
the Curve (AUC) were determined from the resulting ROC
curves. Principle Component Analysis (PCA) to visually reduce
and summarize signal intensity variance among the subjects was
conducted in JMP software (www.JMP.com).
Hierarchical clustering was used to group sera samples into
subsets, such that those within each cluster (subset) are more
closely related to one another than samples assigned to other
clusters. Clustering is based on the degree of similarity between
the protein intensity for each individual.MeV v4.6 (TM4Microarray
Software Suite, www.tm4.org) was used to perform the clustering
analysis.
The following programs were utilized for computational pre-
diction. TMHMM v2.0 was utilized for transmembrane domains
prediction46 (http://www.cbs.dtu.dk/services/TMHMM/), SignalP
v3.0 for signal peptide prediction47 (http://www.cbs.dtu.dk/
services/SignalP/), PSORTb v3.0. software for cellular location
prediction48 (http://www.psort.org/psortb/). PI/MW tool
from Swiss Institute of Bioinformatics was used to determine
isolectric point (http://ca.expasy.org/tools/pi_tool.html). P value
for enrichment statistical analysis was calculated using Fisher’s exact
test in the R environment.
’RESULTS
Gene Amplification, Cloning and Protein Expression
The 3198 predicted ORFs of B. melitensis (Bm) 16 M were
subjected to amplification from genomic DNA, and 1406 ORFs
were cloned and printed on pilot chip.5 In this study, another
1640 ORFs were successfully cloned using our high throughput
recombination method. About one-fourth of the cloned genes
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were sequenced and >99% of sequenced clones had the correct
sequence. All 3046 Bm ORFs cloned in pXT7 vector (>95% of
proteome) were expressed under T7 promoter in the E. coli in
vitro transcription/translation system, and printed on microar-
rays. Over 98% of protein spots were confirmed positive for
expression (Figure S1A, Supporting Information).
Human Antibody Profile
Bm protein arrays were probed with sera from acute brucel-
losis patients in Lima, Peru obtained within 13 weeks of the
onset of symptoms, and sera from Bm culture-positive humans
(Figure S1B, Supporting Information) showed robust reactivity
against a collection of antigens compared to unexposed indivi-
duals. Among the 3046 antigens tested, 1464 antigens reacted
with at least one culture positive individual, accounting for 48%
of the proteome (Figure 1). Within this immunoproteome, 122
protein antigens were defined “serodominant”, with mean re-
activity greater than the mean of the no DNA controls plus 2.5
standard deviations among culture positive individuals (Figure 2,
Figure S2 and Table S1, Supporting Information). Of these, 33
protein antigens were serodiagnostic, and were significantly
differentially reactive between na€ive and culture positive patients
from Peru (Benjamini and Hochberg adjusted Cyber-T p-value
<0.05). Most of these antigens also reacted strongly with sera
from brucellosis cases that were culture negative but positive for
the Rose Bengal diagnostic test. An unbiased hierarchical cluster-
ing analysis segregated most of the individual specimens into two
groups, with a few infected cases with weak reactivity sporadically
clustered among samples diagnosed as uninfected (Figure S2,
Supporting Information). Peruvian na€ive samples exhibited very
low responses to this collection of antigens. We also identified 90
cross-reactive antigens that reacted similarly among all human
Figure 2. Discovery of new human serodiagnostic antigens by probing the full B. melitensis proteome arrays with a collection of B. melitensis Peruvian
na€ive and culture positive human sera. The mean sera reactivity of the 3046 antigens was compared between the culture positive and Peruvian naive
groups. Antigens with Benjamini Hochberg corrected p-value less than 0.05 (serodiagnostic) are organized to the left and cross-reactive (BH_p > 0.05)
antigens to the right. Shown are the 33 serodiagnostic protein antigens, Bm LPS, and a subset of cross-reactive antigens.
Figure 1. Reactivity of the Immunoproteome. Each bar represents one of the 3046 proteins of B.melitensis. The bar height reflect the number of sera
reactive to each protein. Nonreactive proteins account for approximately 52% of the proteome. The raised bars of any color represent 1464 reactive
proteins, which define the immunoproteome (approximately 48% of the proteome). There are 538 antigens reactive in 1 sample, 648 antigens reactive in
25 samples, 143 antigens reactive in 69 samples and 135 antigens reactive in 1042 samples. BMEI0536 and BMEI1079 reacted in all 42 Bm culture
positive samples. All serodiagnostic antigens except BMEI0503 reacted in 1042 samples; BMEI0503 reacted in 9 samples.
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samples, whether from na€ive individuals or individuals diagnosed
to be infected.
Classifier of Serodiagnostic Antigens
We performed unsupervised principal component analysis
and showed that the 33 serodiagnostic antigens clearly separated
the Peruvian naive from culture positive groups (Figure 3A). To
further determine the accuracy of distinguishing brucellosis cases
from controls, cross-validation receiver operating characteristic
(ROC) curves and area under the curve (AUC) boxplots were
generated (Figure 3). The serodiagnostic antigens were ranked
by decreasing single antigen AUC. The top four ORFs, BMEI0536
(bp26), BMEI0805 (hypothetical protein), BMEI1330 (protease
Do), and BMEI 1890 (transporter), as wells as Bm LPS, all have
an individual antigen AUC greater than 0.90 (Table S1, Support-
ing Information). Three of the antigens were identified pre-
viously on microarrays.5 Antigen bp26 (BMEI0536; AUC 0.991;
BH p-value < 1 1016) gave the best single antigen discrimination
with 95% sensitivity and specificity rate. We used kernel methods
and support vector machines43,49 to build linear and nonlinear
classifiers. Variability and mean value of accuracy from this model
has been shown in the AUC boxplot. The top 5 antigens all
produced sensitivity and specificity over 96% (Figure 3C). With
the top 3 antigens, this classifier yielded a highest sensitivity
and specificity rate of 98.6 and 98.6%, respectively. Altogether
33 protein antigens plus LPS produced sensitivity and specificity
over 93%.
Validation of Serodiagnostic Accuracy with Immunostrips
Eighteen serodiagnostic proteins and Bm LPS were printed
onto nitrocellulose membranes using a BioDot jet dispenser. The
membrane was then cut into 3 mm strips. The individual strips
were probed with 31 different randomly selected culture positive
sera and 31 Peruvian naive sera. Brucellosis patients reacted
strongly against the serodiagnostic antigens with variable signal
intensities among the patients. Na€ive samples showed much
lower reactivity against these serodiagnostic antigens (Figure 4A).
The ROC curve (Figure 4B) shows that this immunostrip test
Figure 3. Statistical presentation of principal component analysis and multiple antigens AUC. (A) Unsupervised principal component analysis of the
signal intensity for samples from Peruvian naives and culture positive groups revealed that these two groups could be segregated on the basis of 33
selected serodianosis protein antigens and 2 Bm LPS (at 0.1 mg/mL or 0.01 mg/mL). The serodiagnostic antigens were ranked by single antigen AUC.
(B) Cross-validation AUCboxplot with variance andmean value and (C) cross-validation ROCgraphs show classifiers with increasing number of human
serodiagnostic antigens. With the top 3 antigens, this classifier yielded a highest sensitivity and specificity rate of 98.6% and 98.6%, respectively. All 33
antigens plus Bm LPS also produced sensitivity and specificity over 93%.
Figure 4. Immunostrips probing. (A) Eineteen serodiagnostic antigens and Bm LPS at 0.01 mg/mL were printed onto nitrocellulose membrane in
adjacent stripes using a BioDot jet dispenser as described in Materials and Methods. Strips were probed with culture positive or Peruvian naive sera
diluted 1/200 followed by alkaline phosphatase conjugated secondary antibody and enzyme substrate. Weak reactivity in the na€ive healthy controls can
be distinguished from the strong reactivity in the infected group. (B) Cross-validation ROC curve was generated and sensitivity and specificity of
immunostrips test is 96% and 96%, respectively.
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yielded a high AUC of 0.97, with sensitivity rate of 96.7% and
specificity rate of 96.7%.
Comparing Blood Culture and Serological Testing by
Agglutination
Serological tests are routinely used to diagnose brucellosis.
While the qualitative agglutination test (Rose Bengal) is ∼90%
sensitive for screening for acute/subacute brucellosis,50,51 quantitative
agglutination testing (e.g., tube agglutination test (TAT)) with
titer typically greater than 1/160 used as a more precise diagnostic
criterion, can also be used to diagnose relapse. Often blood
cultures are negative at the time of initial presentation or relapse,
possibly because of low levels of bacteremia or antecedent use of
antibiotics. Without being able to ascertain whether the sera used
in this study were obtained from patients who might have taken
antibiotics prior to blood cultures, we queried our data set to
Figure 5. Overview of an enrichment analysis of Bm proteome classified with COGs and computational predictions categories. (A) Overview of Bm
proteome classified with a total of 3291 COGs. The size of each slice represents the number of proteins assigned to each COG category. Proteins
classified with COGs-U,M, N, O categories are significantly overrepresented in serodominant antigens and shown in extracted red. COG-K proteins are
significantly underrepresented in serodominant antigens are shown in extracted black. COG categories with <5 proteins were not included in the figure
(COGs-B, W). (B) Computational predictions for the Bm proteome are shown. Significant over- and under-representations are shown in extracted red
or black, respectively. Numbers of serodominant antigens within these categories/number of total proteins within these categories are in parentheses in
the legend. Results of the complete COG analysis and computational predictions are in Table S3 (Supporting Information). (C) Correlation between
enrichment fold and peptide numbers detected by Mass Spectrometry. As peptide numbers for serdiagnostic antigens increase, enrichment fold for
serodiagnostic antigens also increases. In contrast, enrichment fold for cross-reactive antigens decreases as peptide numbers for cross-reactive antigens
increase.
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determine whether sera from blood culture-positive, Rose Bengal
positive brucellosis patients (gold standard diagnosis) vs blood
culture-negative, Rose Bengal positive (TAT not done) subjects
(presumptive positive, unconfirmed) recognized different pro-
teins on the protein microarrays. Sera from blood culture-negative,
Rose Bengal positive subjects reacted with 10 B. melitensis
antigens much more strongly than blood culture-positive, Rose
Bengal positive individuals (Figure S3, Supporting Information).
This unique set of 10 antigens was distinct from the 33 antigens
that distinguish culture positive cases from Peruvian na€ives.
(Table S2, Supporting Information). These results indicate that
protein microarray analysis was able to delineate distinct anti-
body profiles in blood culture positive and negative patients,
which has the potential to identify antigens capable of differ-
entiating active acute/subacute brucellosis from previously ex-
posed patients. These findings may suggest novel biological
interactions between bacteria and host that need to be further
explored because culture negativity/Rose Bengal seropositivity
might be associated with some biological difference between
human hosts, perhaps an immune response that might lower
bacterial loads to levels difficult to culture from blood. Alterna-
tively, it is possible that antibiotic use might lead to an altered
host immune response to killed bacteria that no longer would
subvert the host immune responses (typical of intracellular
pathogens such as Brucella).5254
Enrichment Analysis
To better understand the determinants of antigenicity in
bacteria, we performed a functional enrichment analysis of the
serodominant and serodiagnostic antigens identified in this
study. Bm proteins are annotated with NCBI Clustered Ortho-
logous Group (COG) functional category. A total of 543 proteins
are unassociated with COGs, and 39 proteins are associated with
COGs but have not been assigned to a category, shown as “Other
COGs”. Some proteins have multiple COG assignments so there
are 3,291 COGs in total for 3046 proteins on chip.
Proteins with predicted COG- U function, involved in intra-
cellular trafficking and secretion, were 6.2- fold enriched in
serodiagnostic antigens and 4.3- fold enriched in serodominant
antigens. The enrichment was significant with p value <0.05.
Proteins in the COG-M category, cell envelope biogenesis and
outer membrane, were 2-fold enriched in serodominant antigens
(p-value 0.01). Proteins in COG-N category, cell motility and
secretion, were 3.5-fold enriched in serodominant antigens (p =
0.027). Proteins with predicted COG-O function, posttranslational
modification, protein turnover, chaperones, were also significantly
enriched at 3.0-fold in serodominant antigens. There was only 1
serodominant antigen out of 176 COG-K category proteins,
predicted to be involved in transcription and identified as sero-
dominant, which was 0.1- fold enrichment and significantly
underrepresented with p value of 0.014 (Figure 5A, Table S3A,
Supporting Information).
We also looked at enrichment of antigens using computation-
ally predicted features. As shown in Figure 5B and Table S3B
(Supporting Information), proteins with 1 transmembrane do-
main were significantly enriched in serodominant, serodiagnostic
and cross-reactive antigens groups, with enrichment fold at 4.3,
5.0, and 4.0, respectively. Proteins lacking transmembrane domains
were significantly underrepresented. Interestingly, proteins with
more than 1 transmembrane domain were also significantly under-
represented among the serodominant and cross-reactive anti-
gens. Proteins with predicted signal peptides (SignalP score > 0.7)
were significantly enriched in all three groups at a range of 2.8- to
3.6-fold. Conversely, proteins without signal peptides (SignalP
score < 0.7) were significantly underrepresented. pSortb pre-
dicted 4 serodiagnostic and 5 serodominant outermembrane
antigens, resulting in 11.5- and 3.9-fold enrichment, respectively.
pSortb periplasmic proteins were also significantly enriched,
from 3.1- to 4.2-fold. However, pSortb cytoplasmic proteins
were 0.5- to 0.7-fold underrepresented in serodominant and
serodiagnostic antigens groups. We also found that proteins with
isoelectric points lower than 5 were 1.7- to 2.0-fold enriched in
serodominant and cross-reactive antigen groups, whereas, pro-
teins with pI = 9 to 14 were 0.6- and 0.5-fold underrepresented in
these two groups.
Another potential feature that could account for protein
antigenicity is the level of in vivo expression; proteins expressed
at a high level in vivo would be expected more likely to be seen
by the immune system than proteins expressed at a low level. To
test this hypothesis, we compared the group of antigenic
B. melitensis proteins with an existing data set of expressed protein
peptide data from a very closely related species, B. abortus.23,35,36
In this study, cytosolic proteins and cell envelope proteins from
B. abortus in the log phase of in vitro growth, were extracted and
subjected to LCMass spectrometry (MS) analysis as described
in Materials and Methods. The number of different peptides
identified for each protein was listed in Table S4 (Supporting
Information). Two-hundred forty proteins were exclusively ex-
pressed in the cytosol of B. abortus with 1 to12 detected peptides,
and 53 proteins exclusively expressed in the cell envelope of
B. abortus with 1 to 15 detected peptides, and 80 overlapping
proteins expressed in both conditions. Of these, 356 proteins
Table 1. Enrichment Analysis for B. abortus Homolog Proteins Expressed during in vitro Growth As Detected by Mass
Spectrometrya
proteins serodominant serodiagnostic cross-reactive
B. abortus homologs expression on chip hits FoldEnrich p-value hits FoldEnrich p-value hits FoldEnrich p-value
Expressed and detected with at least 1 peptide 356 41 2.9 5.28E-11 20 5.2 1.87E-11 21 2.0 0.001
Expressed and detected with at least 2 peptides 175 23 3.3 2.04E-07 16 8.4 3.56E-12 7 1.4 0.353
Expressed and detected with at least 5 peptides 40 8 5.0 1.38E-04 7 16.2 1.30E-07 1 0.9 1.000
Expressed and detected with at least 7 peptides 16 4 6.2 3.07E-03 4 23.1 1.90E-05 0 0.0 1.000
Expressed and detected with at least 9 peptides 9 2 5.5 4.76E-02 2 20.5 3.91E-03 0 0.0 1.000
Not expressed 2690 81 0.8 5.28E-11 13 0.4 1.87E-11 68 0.9 0.001
Total ORFs 3046 122 33 89
a Significant enrichment or underrepresentation for certain features are underlined and bold.
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were printed on our proteome chip. Not surprisingly, expression
was a significant enriching feature with 5.2-fold enrichment
among serodiagnostic antigens (p-value 1.87  1011), and 2.9-
fold in serodominant antigens (p-value 5.28 1011) (Table 1).
Interestingly, the fold enrichment was directly proportional to
the number of peptides detected (Figure 5C). There was 8.4- fold
enrichment of serodiagnostic antigens in proteins detected with
more than 1 peptide (p-value 3.56  1012), 16.2- fold in pro-
teins detected with 5 or more peptides (p-value 1.30  107),
23.1- fold enrichment in proteins detected with 7 or more
peptides (p-value 1.90  105), and 20.5-fold enrichment in
proteins detected with 9 or more peptides (p-value 3.91 103).
Conversely, proteins that were not identified by MS were signif-
icantly underrepresented at 0.4-fold among the serodiagnostic and
0.8-fold among serodominant antigens. The data suggests that
protein expression level is an important factor contributing to
antigenicity of protein antigens. This was also supported by data
in other experimental systems from different research groups.55
There are a total of 10 enriching features that fall into 3
categories: (i) functionally annotated COGs U, M, N and O, (ii)
computationally predicted features (TMHMM=1, SignalP > 0.7,
pSort Outermembrane, pSort Periplasmic, and pI < 5), and
(iii) MS evidence of expression. The Venn diagrams summarize
the number of enriched proteins found in each of these 3
categories, showing overlap among the proteins found in each
category (Figure 6). There are 338 proteins in the enriched COG
categories, 696 computationally predicted proteins, and 356
proteins that were positive by MS (Table 2). Accounting for
the overlap between categories, 1128 proteins in all enriched
categories represented 37% of the proteome. The microarray
results empirically identified 33 serodiagnostic antigens and 89
cross-reactive antigens. COGs accounted for 30% of the sero-
diagnostic hits, the computationally predicted features accounted
for 61% of the hits, and MS positive proteins contained 61% of
the hits. All together the three categories account for 37% of the
proteome and include 91% of the serodiagnostic antigens. But
there is only 1 unique serodiagnostic COG antigen that is not
represented in either the computationally predicted or MS+
categories (BMEI1060, Table S1, Supporting Information). So
by combining the pool of computationally predicted and MS+
proteins representing 30% of the proteome, 88% of the sero-
diagnostic antigens can be predicted.
Table 2. Enrichment Summary for Antigens with Categorized Enriching Featuresa
whole genome (3046 on chip) cross-reactive (89 total) serodiagnostic (33 total)
enriching features predicted % of total predicted % of total predicted % of total
COGs-U, M, N, O 338 11% 27 30% 10 30%
Computationally Predicted 696 23% 47 53% 20 61%
Mass Spectrometry Positive (MS+) 356 12% 21 24% 20 61%
COGs + Predicted 919 30% 60 67% 22 67%
COGs + Predicted + MS+ 1128 37% 69 78% 30 91%
Predicted + MS+ 925 30% 58 65% 29 88%
a Enriching features are classified into three categories: (1) COGs-UMNO, for proteins assigned to one ormore of these four COGs; (2) Computational
predictions with enriching features, for proteins predicted to have one or more of the following features, i.e., TMHMM = 1, SignalP > 0.7, pSort
Outermembrane, pSort Periplasmic, or pI < 5; and (3) Protein expression as detected bymass spectrometry. Numbers of overlapping antigens for two or
three categories are shown in Figure 6.
Figure 6. Venn diagram of numbers of antigens with categorized enriching features. Enriching features are classified into three categories: (1) COGs-
UMNO, for proteins assigned to one or more of these four COGs; (2) Computational predictions with enriching features, for proteins predicted to have
one or more of the following features, that is, TMHMM = 1, SignalP > 0.7, pSort Outermembrane, pSort Periplasmic, or pI < 5, and (3) Protein
expression as detected by peptide presence in Mass Spectrometry. Separately shown are numbers of antigens with enriching features, including all such
1128 antigens on chip, 99 serodominant, and 30 serodiagnostic antigens. Numbers of antigens having more than one category of enriching features are
also presented in the overlapping region of such categories.
4821 dx.doi.org/10.1021/pr200619r |J. Proteome Res. 2011, 10, 4813–4824
Journal of Proteome Research ARTICLE
’DISCUSSION
Today with increasing efficiency, accuracy and speed we access
completed genome sequences from thousands of infectious micro-
organisms. However, systems- level studies to understand the
complete network of antibody responses have not been widely
performed. This work was motivated by the disturbing lack of a
detailed scientific understanding of the antibody responses to
infectious diseases.We have been taking a systems biology approach
to account for all of the antibodies that develop after exposure to
infectious microorganisms and to identify specific antibody signa-
tures associated with each disease, in order to understand the
molecular basis for antigen selection by the immune system and
to predict serodiagnostic and vaccine antigens targets.
This study is the first full proteome-wide serological analysis of
B. melitensis. Our previous study identified a set of serodiagnostic
antigens from a randomly selected half of the B. melitensis proteome.
However, an important difference between the present study and
this previous report is that analysis of the complete proteome not
only has allowed us to delineate additional serodiagnostic antigens
but, more fundamentally, also provided the basis for a rigorous,
comprehensive and quantitative determination of basic biologi-
cal characteristics of the entire set of the serodominant antigens
on a genomic level.
The current standard serological screening assay, an aggluti-
nation test that uses tinted, killed bacteria as antigen (Rose
Bengal) is based primarily on identification of antibodies to LPS
in patient serum. In the present microarray study, we confirmed
LPS reactivity (with purified LPS spotted onto the microarray),
and identified novel protein antigens. The signature antigens
were validated using traditional Western blots. Although anti-
body responses against all 33 protein antigens used together can
predict disease with 92% accuracy, using the serological re-
sponses against the top 3 individual antigens together improves
accuracy to >98% for diagnosis of acute human brucellosis. One
limitation is that the humans studied here only had acute or
subacute brucellosis-fever but not focal or chronic disease. Future
studies are needed to assess suspected cases that are agglutination
test negative, for example chronic neurobrucellosis or focal
disease such as orchitis or vertebral osteomyelitis.
Eleven of the 33 serodiagnostic antigens identified in this
study were also identified on the pilot array5 (Table S1, Support-
ing Information). Our findings are in good agreement with
published studies that identified well characterized antigens from
other Brucella spp, including Bp26 (BMEI0536),20,25,31,56 HtrA/
DegP (BMEI1330),28 Omp16 (BMEI0340),29 the chaperonin
GroEL protein (BMEII1048) andOmp 10 (BMEII0017).21,57 In
addition to the well characterized antigens, we also identified 21
novel serodiagnostic antigens on the current array, including top
antigen hypothetical protein BMEI0805. Two pyruvate dehy-
drogenase complex molecules and the associated acetyl CoA
hydrolase, which together form a large multimeric structure con-
sisting of 60 subunits, are also differentially recognized; this large
enzyme complex is found in most bacteria and is frequently a
target of immune recognition for other infections.6,58
Protein microarrays enable enrichment analyses to identify
proteomic features that are enriched in the immunodominant
antigen set, and development of protein antigenicity prediction
tools based on enriched features. The prediction tools then can
be applied on a high-throughput scale to existing or new proteomes
to identify key antigenic proteins that may have serodiagnostic or
protective characteristics. Enrichment analysis identified10proteomic
features that are enriched in the serodiagnostic signature anti-
gens. The proteomic features fall into 3 categories: (i) COG
annotations, (ii) computationally predicted proteomic features,
and (iii) proteins with MS evidence of expression in viable
organisms. No single proteomic feature or category of features
is sufficient to identify all these signature antigens. Our data
suggests that cloning of 37% of genome with these enriching
features would reveal more than 90% of serodiagnostic antigens.
We have classified the reactive immunodominant antigens for
numerous agents and have consistently found these features
predict antigenicity.6,7,10,59
These results describe the relationship between antigenicity
and in vivo expression of individual proteins. In our study, we
utilized the expression of proteins quantified by MS of a closely
related strain, B. abortus during in vitro growth. We found that
mass spec positive antigens were significantly enriched among
serodiagnostic antigens but not among the cross- reactive anti-
gens. This validates the classification of the serodiagnostic
antigens being derived from actively replicating organisms, and
validates the classification of cross-reactive antigens being de-
rived from previous exposure to nonbrucellosis infections.
Although the number of peptides observed per protein has been
applied to estimating protein abundance,6062 we are aware that
mass spectra of cultured organismsmay not reflect the expression
during infection in vivo. First, nutrients are not limiting in log
phase growth in vitro, whereas in vivo, Brucella is likely to be
within a nutrient-limited intracellular environment.63 Second,
the MS method may not be particularly quantitative, especially
for membrane proteins. Our protein array technology is also
able to provide strong evidence of the comprehensive set of
proteins expressed in vivowithin amammalian host byB.melitensis,
by virtue of their exposure to the host immune system. The
expression and abundance of proteins during in vivo growthmerits
further examination by other novel technologies, such as measure-
ment of transcript abundance fromRNA-seq (“deep sequencing”)
technique.64
The B. melitensis immunoproteome comprises 1464 antigens
that are significantly reactive in at least one of the individuals in
this study. Only 122 serodominant antigens are significantly
recognized by most of the individuals. Answers to questions of
why and how the immune system focuses on 4% of the potential
target antigens are not yet apparent from this work. One might
expect that an immune response against a larger collection of
antigens could result in a more effective immune response attack
against the infectious agent. But antibody responses against
thousands of antigens from hundreds of clinical infections could
accumulate during a lifetime, leading to cross reactivity against
autologous antigens and autoimmune chaos. This could provide
evolutionary selection pressure favoring amore focused response
to infection. The observation that dozens of organism- specific
antibody responses develop after B. melitensis infection is con-
sistent with similar observations from other infectious agents,
and has implications for subunit vaccine discovery and develop-
ment. Mimicking the natural response to infection could be
considered a viable strategy for vaccine development but most
subunit vaccines aim to derive protection from immunization
with only a single antigen. Attenuated or killed whole organism
vaccines produce an antibody reactivity profile against dozens of
antigens more similar to natural infection.6
This systematic genome scale analysis of human antibody
responses against B. melitensis proteins provides a top hit list of
antigens worthy of assessing for improved diagnostics, and
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furthermore, enables development of a predictive model of
proteomic features that determine whether a protein is antigenic
and produces antibodies that confer protection. This systems
biology approach provides an empirical basis for understanding
the breadth and specificity of the immune response to B. melitensis
and a new framework for comparing the humoral responses
against other organisms.
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